Botanix Pharmaceuticals Limited Return on Equity

Botanix Pharmaceuticals Limited (BXPHF) currently reports a ROE of -246.09%. That is below the Healthcare sector average of -75.59%. Use the charts on this page to explore Botanix Pharmaceuticals Limited's ROE history and peer comparisons.

Botanix Pharmaceuticals Limited's ROE of -246.09% is lower than the Healthcare sector average of -75.59%. That is roughly 225.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Botanix Pharmaceuticals Limited's current -246.09% should be judged against Healthcare norms (sector average: -75.59%) and against BXPHF's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -246.09%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.59%. From there, open related valuation or income-statement pages for Botanix Pharmaceuticals Limited, and consider following BXPHF for alerts when major investors trade the stock.

Botanix Pharmaceuticals Limited is classified in the Healthcare sector. On ROE, it currently shows -246.09% versus a sector average near -75.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BXPHF with unrelated industries.